Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02099058 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
- 20
- Study locations
NCT02099058: Active Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
NCT02099058 is a Phase 1 study of Advanced Solid Tumors Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 237 participants, below the 328-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02099058, a Phase 1 study of Advanced Solid Tumors Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Nivolumab
- DRUG Erlotinib
- DRUG Telisotuzumab vedotin
Study Locations (20)
California
- City of Hope /ID# 153759 - Duarte
- University of California, Los Angeles /ID# 148295 - Los Angeles
- UC Irvine /ID# 165107 - Orange
- University of California, Davis Comprehensive Cancer Center /ID# 129805 - Sacramento
Illinois
- The University of Chicago Medical Center /ID# 136995 - Chicago
- Ingalls Memorial Hosp /ID# 165876 - Harvey
Massachusetts
- Massachusetts General Hospital /ID# 129804 - Boston
- Dana-Farber Cancer Institute /ID# 168782 - Boston
Michigan
- Duplicate_Henry Ford Health System /ID# 149857 - Detroit
- Herbert Herman Cancer Center /ID# 149858 - Lansing
New York
- Northwell Health - Monter Cancer Center /ID# 218170 - Lake Success
- Montefiore Medical Park at Eastchester /ID# 218445 - The Bronx
Texas
- Mary Crowley Cancer Research /ID# 123760 - Dallas
- University of Texas MD Anderson Cancer Center /ID# 154648 - Houston
Arizona
- Scottsdale Healthcare /ID# 123761 - Scottsdale
Colorado
- Univ of Colorado Cancer Center /ID# 123759 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2014-01-15 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
What the registry record for NCT02099058 still lists
NCT02099058 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, below the 328-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 4 interventions - of which Osimertinib is the first listed.
NCT02099058 names 20 study sites across 12 states, led by California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02099058 about?
NCT02099058 is a clinical study titled "A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors". This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monot...
What is the current status of trial NCT02099058?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2014-01-15. Estimated completion is 2026-08.
What conditions does trial NCT02099058 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT02099058?
The interventions under investigation include: Osimertinib (DRUG), Nivolumab (DRUG), Erlotinib (DRUG), Telisotuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT02099058?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02099058 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02099058's enrollment target sits among peer trials
237 3rd of 9 higher than 7 of 9 other Advanced Solid Tumors Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI